A phase Ⅰ study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer

Objective: Hemay022 is a novel small-molecule and an irreversible tyrosine kinase inhibitor with the target of epidermal growth factor receptor(EGFR)/human epidermal growth factor receptor 2(HER2), which demonstrated anti-tumor activity in preclinical studies. This first-in-human study evaluated the safety, pharmacokinetics,tolerability and preliminary anti-tumor activity of Hemay022 in HER2-positive advanced breast cancer patients.Methods: Heavily pretreated patients with HER2-positive advanced breast cancer were assigned to eight dose cohorts in a 3+3 dose-escalation pattern at doses of 50-600 mg QD and 300 mg BID. Eligible patients were given a single dose of Hemay022 on d 1 in week 0, followed by once daily continuous doses for four weeks in 28-day cycles.Pharmacokinetic samples were obtained on d 1 and d 28. Clinical responses were assessed every eight weeks.Results: Twenty-eight patients with advanced breast cancer were treated with Hemay022. The most frequently reported drug-related adverse events were diarrhoea(85.7%), vomiting(28.6%), nausea(25.0%) and decreased appetite(17.9%). No grade 4 drug-related adverse events were reported. At 50-600 mg doses, steady state areas under the concentration-time curve and peak concentrations increased with doses. One patient achieved complete response(CR), and three achieved partial response(PR). The objective response rate(ORR) and disease control rate(DCR) were 14.3% and 46.4% in 28 patients, respectively. The median progression-free survival(PFS) was3.98 months.Conclusions: Hemay022 at the dose of 500 mg once daily was well tolerated. The pharmacokinetic properties and encouraging anti-tumor activities of Hemay022 in advanced breast cancer patients warranted further evaluation of Hemay022 for treating breast cancer patients in the current phase Ⅲ trial(No. NCT05122494).

Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase Ⅱ single-arm study

Objective: Despite cardiotoxicity overlap, the trastuzumab/pertuzumab and anthracycline combination remains crucial due to significant benefits. Pegylated liposomal doxorubicin(PLD), a less cardiotoxic anthracycline, was evaluated for efficacy and cardiac safety when combined with cyclophosphamide and followed by taxanes with trastuzumab/pertuzumab in human epidermal growth factor receptor-2(HER2)-positive early breast cancer(BC).Methods: In this multicenter, phase II study, patients with confirmed HER2-positive early BC received four cycles of PLD(30-35 mg/m^(2)) and cyclophosphamide(600 mg/m^(2)), followed by four cycles of taxanes(docetaxel,90-100 mg/m^(2) or nab-paclitaxel, 260 mg/m^(2)), concomitant with eight cycles of trastuzumab(8 mg/kg loading dose,then 6 mg/kg) and pertuzumab(840 mg loading dose, then 420 mg) every 3 weeks. The primary endpoint was total pathological complete response(tp CR, yp T0/is yp N0). Secondary endpoints included breast p CR(bp CR),objective response rate(ORR), disease control rate, rate of breast-conserving surgery(BCS), and safety(with a focus on cardiotoxicity).Results: Between May 27, 2020 and May 11, 2022, 78 patients were treated with surgery, 42(53.8%) of whom had BCS. After neoadjuvant therapy, 47 [60.3%, 95% confidence interval(95% CI), 48.5%-71.2%] patients achieved tp CR, and 49(62.8%) achieved bp CR. ORRs were 76.9%(95% CI, 66.0%-85.7%) and 93.6%(95% CI,85.7%-97.9%) after 4-cycle and 8-cycle neoadjuvant therapy, respectively. Nine(11.5%) patients experienced asymptomatic left ventricular ejection fraction(LVEF) reductions of ≥10% from baseline, all with a minimum value of >55%. No treatment-related abnormal cardiac function changes were observed in mean N-terminal pro-BNP(NT-pro BNP), troponin I, or high-sensitivity troponin.Conclusions: This dual HER2-blockade with sequential polychemotherapy showed promising activity with rapid tumor regression in HER2-positive BC. Importantly, this regimen showed an acceptable safety profile,especially a low risk of cardiac events, suggesting it as an attractive treatment approach with a favorable risk-benefit balance.

Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer

BACKGROUND Patients with human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer have poor outcomes.Trastuzumab combined with chemotherapy is the first-line standard treatment for HER2-positive advanced gastric cancer.Inetetamab is a novel anti-HER2 drug,and its efficacy and safety in gastric cancer have not yet been reported.AIM To evaluate the efficacy and safety of the S-1 plus oxaliplatin(SOX)regimen combined with inetetamab as a first-line treatment for HER2-positive advanced gastric cancer.METHODS Thirty-eight patients with HER2-positive advanced gastric cancer or gastroeso-phageal junction adenocarcinoma were randomly divided into two groups:One group received inetetamab combined with the SOX regimen,and the other group received trastuzumab combined with the SOX regimen.After 4-6 cycles,patients with stable disease received maintenance therapy.The primary endpoints were progression-free survival(PFS)and overall survival(OS),and the secondary endpoints were the objective response rate,disease control rate,and adverse events(AEs).RESULTS Thirty-seven patients completed the trial,with 18 patients in the inetetamab group and 19 patients in the trastuzumab group.In the inetetamab group,the median PFS was 8.5 months,whereas it was 7.3 months in the trastuzumab group(P=0.046);this difference was significant.The median OS in the inetetamab group vs the trastuzumab group was 15.4 months vs 14.3 months(P=0.33),and the objective response rate was 50%vs 42%(P=0.63),respectively;these differences were not significant.Common AEs included leukopenia,thrombocytopenia,nausea,and vomiting.The incidence rates of grade≥3 AEs were 56%in the inetetamab group and 47%in the trastuzumab group(P=0.63),with no significant difference.CONCLUSION In the first-line treatment of HER2-positive advanced gastric cancer,inetetamab and trastuzumab showed comparable efficacy.The inetetamab group showed superior PFS,and both groups had good safety.

Quercetin inhibits truncated isoform of dopamine-and cAMP-regulated phosphoprotein as adjuvant treatment for trastuzumab therapy resistance in HER2-positive breast cancer

Trastuzumab resistance is one of the causes of poor prognosis in patients with human epidermal growth factor receptor 2(HER2)-positive(HER2+)breast cancer(BC).The truncated isoform of dopamine-and cAMPregulated phosphoprotein(t-DARPP)has been reported to be involved in trastuzumab therapy resistance and promoting tumor progression.To evaluate the t-DARPP expression in BC,paired tumors and surrounding normal tissues were analyzed by real-time polymerase chain reaction and confirmed higher DARPP-32 kDa family mRNA expression in HER2+BC tumor tissues.We established 2 patient-derived xenografts(PDX)mice models to test the efficacy of trastuzumab,named model 1(non-responder)and model 2(responder).t-DARPP and p95-HER2 protein-protein interactions were detected in PDX tumor tissue from non-responders using Förster resonance energy transfer assays.Instead,there is no response from the responder.Furthermore,mechanistic studies using transwell and western blot assays demonstrated that t-DARPP could upregulate epithelial-mesenchymal transition signaling proteins,enhance p95-HER2 expression and promote cell migration.We found that quercetin effectively reduced t-DARPP expression in HER2+BC cells.In t-DARPP ShRNA-suppressed cells,quercetin synergistically enhanced trastuzumab-induced apoptotic cell death and G2/M phase arrest.In conclusion,the combination of quercetin and trastuzumab treatment by targeting t-DARPP in HER2+BC patients has the potential as a biomarker for mitigating drug resistance.

A multicenter study on efficacy of dual-target neoadjuvant therapy for HER2-positive breast cancer and a consistent analysis of efficacy evaluation of neoadjuvant therapy by Miller-Payne and RCB pathological evaluation systems(CSBrS-026)

Objective: The aim of this study was to investigate the factors influencing pathological complete response(pCR)rate in early breast cancer patients receiving neoadjuvant dual-target [trastuzumab(H) + pertuzumab(P)] therapy combined with chemotherapy. Additionally, the consistency of the Miller-Payne and residual cancer burden(RCB)systems in evaluating the efficacy of neoadjuvant therapy for early human epidermal growth factor receptor-2(HER2)+ breast cancer was analyzed.Methods: The clinicopathological data of female patients with early-stage HER2+ breast cancer who received dual-target neoadjuvant therapy at 26 hospitals of the Chinese Society of Breast Surgery(CSBrS) from March 2019 to December 2021 were collected. Patients were allocated to four groups: the HER2 immunohistochemistry(IHC)3+/hormone receptor(HR)-, IHC3+/HR+, IHC2+ in situ hybridization(ISH)+/HR-and IHC2+ ISH+/HR+groups. The overall pCR rate for patients, the pCR rate in each group and the factors affecting the pCR rate were analyzed. The consistency between the Miller-Payne and RCB systems in assessing the efficacy of neoadjuvant therapy was analyzed.Results: From March 1, 2019, to December 31, 2021, 77,376 female patients with early-stage breast cancer were treated at 26 hospitals;18,853(24.4%) of these patients were HER2+. After exclusion of unqualified patients, 2,395 patients who received neoadjuvant dual-target(H+P) therapy combined with chemotherapy were included in this study. The overall pCR rate was 53.0%, and the patients' HR statuses and different HER2+ statuses were significantly correlated with the pCR rate(P<0.05). The consistency of the pathological efficacy assessed by the Miller-Payne and RCB systems was 88.0%(κ=0.717, P<0.001).Conclusions: Different HER2 expression statuses and HR expression statuses are correlated with the pCR rate after dual-target neoadjuvant therapy in HER2+ breast cancer patients. There is a relatively good consistency between Miller-Payne and RCB systems in evaluating the pathologic efficacy of neoadjuvant therapy for HER2+breast cancer.

Effect of CO_(2)flooding in an oil reservoir with strong bottom-water drive in the Tahe Oilfield,Tarim Basin,Northwest China

The dissolution and diffusion of CO_(2)in oil and water and its displacement mechanism were investigated by laboratory experiment and numerical simulation for Block 9 in the Tahe oilfield,a sandstone oil reservoir with strong bottom-water drive in Tarim Basin,Northwest China.Such parameters were analyzed as solubility ratio of CO_(2)in oil,gas and water,interfacial tension,in-situ oil viscosity distribution,remaining oil saturation distribution,and oil compositions.The results show that CO_(2)flooding could control water coning and increase oil production.In the early stage of the injection process,CO_(2)expanded vertically due to gravity differentiation,and extended laterally under the action of strong bottom water in the intermediate and late stages.The CO_(2)got enriched and extended at the oil-water interface,forming a high interfacial tension zone,which inhibited the coning of bottom water to some extent.A miscible region with low interfacial tension formed at the gas injection front,which reduced the in-situ oil viscosity by about 50%.The numerical simulation results show that enhanced oil recovery(EOR)is estimated at 5.72%and the oil exchange ratio of CO_(2)is 0.17 t/t.

Strong hetero-interface interaction in 2D/2D WSe_(2)/ZnIn_(2)S_(4) heterostructures for highly-efficient photocatalytic hydrogen generation

Green hydrogen is urgently required for sustainable development of human beings and rational construction of heterostructures holds great promising for photocatalytic hydrogen generation.Herein,2D/2D WSe_(2)/ZnIn_(2)S_(4) heterostructures with strong hetero-interface interaction and abundant contact were constructed via an impregnation-annealing strategy.Efficient charge transfer from ZnIn_(2)S_(4) to WSe_(2)was evidenced by transient absorption spectroscopy in crafted heterostructures owing to the tight and2D face-to-face contact.As a result,the prepared WSe_(2)/ZnIn_(2)S_(4) heterostructures exhibited boosted photocatalytic performance and a highest hydrogen evolution rate of 3.377 mmol/(g h)was achieved with an apparent quantum yield of 45.7%at 420 nm.The work not only provides new strategies to achieve efficient 2D/2D heterostructures but also paves the way for the development of green hydrogen in the future.

Antibody-Coupled Drugs in HER2-Positive Gastric Cancer

Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic drugs with antibody drugs through a linker. Antibody drug conjugates combine the targeting characteristics of traditional antibody drugs with the cytotoxic characteristics of small molecule drugs, while reducing the side effects of both drugs, making them a kind of “biological missile” and representing a relatively new and evolving class of anti-cancer drugs. Antibody-coupled drugs are currently used in many solid tumors, and this article reviews the clinical application of antibody-coupled drugs in HER2-positive gastric cancer.

准噶尔盆地东部北10井区中深层稠油CO_(2)非混相驱油技术

准噶尔盆地东部北10井区头屯河组油藏具有埋藏深、原油黏度大、储层强水敏的特点,自探明以来一直未获得有效动用。为了解决油藏难动用的难题进行了CO_(2)-稠油实验,在实验结果的基础上,根据试验区生产现状提出“非混相驱+吞吐”措施,利用数值模拟手段优化生产参数得到最优方案并预测出生产指标。结果表明:地层稠油注入CO_(2)后原油体积膨胀和黏度降低的能力大幅增强,是提高采收率的主要机理;井区稠油CO_(2)驱替方式为非混相驱,驱替过程中CO_(2)先以溶解和扩散作用为主,待建立驱替通道后才开始产出原油,采收率为29.60%;试验区非混相驱初期见效慢,为加快受效提出“油井吞吐”措施,数值模拟预测非混相驱配合3轮油井吞吐生产,最终采收率可达21.0%,解决了研究区油藏难动用的难题。研究成果对中深层强水敏稠油油藏的动用具有一定的借鉴意义。

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer

Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in approximately 15–20% of breast cancer cases. HER2 is a member of the epidermal growth factor receptor (EGFR) family with tyrosinase kinase activity, and its overexpression is linked to poor prognosis and shorter progression-free survival (PFS) and overall survival (OS). Among various treatment options, HER2-targeting monoclonal antibodies and tyrosine kinase inhibitors (TKIs) have mostly been applied in recent decades to treat HER2-positive (HER2^(+)) breast cancer patients. Although positive clinical outcomes were documented in both advanced disease and neoadjuvant settings, the development of resistance mechanisms to such approaches has been one of the major challenges with the continuous usage of these drugs. In addition, patients who experience disease progression after treatment with multiple HER2-targeted therapies often have limited treatment options. The Food and Drug Administration (FDA) has recently approved a new TKI (i.e., tucatinib) for use in combination with immunotherapy and/or chemotherapeutic agents for the treatment of advanced-stage/metastatic HER2^(+) breast cancer. This review highlights recent updates on the efficacy of tucatinib-based therapeutic approaches in experimental models as well as in the clinical settings of HER2^(+) breast cancer.

基于光学影像相关性匹配技术的2023年土耳其M_(W)7.8与M_(W)7.5双强震地表同震变形研究

2023年2月6日在土耳其中南部卡赫拉曼马拉什省10个小时内连续发生M_(W)7.8与M_(W)7.5双强震,震源机制解表明两个地震均为走滑型地震。土耳其双强地震发生后,国内外学者利用野外测量、GNSS以及差分InSAR等方法开展了一系列地表同震变形研究,但由于所采用的技术手段限制,当前已有地表同震变形结果尚存在空间分辨率低、近断层处数据缺失等不足。为了弥补这些不足,研究利用哨兵2号光学影像数据,通过影像相关性匹配技术得到了土耳其双强震的东西向和南北向的地表同震变形场,并将这些地表变形转换成为沿着断层方向的左旋走滑位移。变形场结果显示两次地震地表破裂长度分别约280 km和约130 km,首先发生的M_(W) 7.8地震的平均走滑位移量为4.2±1.66 m,最大走滑位移量6.9±0.81 m;随后发生的M_(W)7.5地震的平均走滑位移量为4.9±2.45 m,最大走滑位移量为9.6±1.16 m。通过对比COSI-Corr方法和野外测量得到的水平位移,结果显示2种方法得到的最大水平位移相吻合,而COSI-Corr方法得到的平均位移略大于野外测量得到的水平位移,这是由COSI-Corr方法测量结果中包含了部分离断层弥散变形导致的。研究结论不仅可为断层面滑动反演模型提供变形数据和约束条件,同时可以加深对走滑断裂的破裂行为控制因素的理解。

Amine-functionalized metal organic framework@graphene oxide as filler in PAEK-containing carboxyl group membrane for ultrafiltration with ultra-high permeability and strong fouling resistance

Achieving high fouling resistance and permeability using membrane separation technology in water treatment processes remains a challenge.In this work,a novel mixed-matrix membrane(MMM)(poly(arylene ether ketone)[PAEK]-containing carboxyl groups[PAEK-COOH]/UiO-66-NH_(2)@graphene oxide[GO])with superb fouling resistance and high permeability was prepared by the nonsolvent-induced phase separation method,by in-situ growth of UiO-66-NH_(2) on the GO layer,and by preparing hydrophilic PAEK-COOH.On the basis of the structure and performance analysis of the MMM,the maximum water flux reached 591.25 L·m^(-2)·h^(-1) for PAEK-COOH/UiO-66-NH_(2)@GO,whereas the retention rate for bovine serum albumin increased from 85.40%to 94.87%.As the loading gradually increased,the hydrophilicity of the MMMs increased,significantly enhancing their fouling resistance.The strongest anti-fouling ability observed was 94.74%,which was 2.02 times greater than that of the pure membrane.At the same time,the MMMs contained internal amide and hydrogen bonds during the preparation process,forming a cross-linked structure,which further enhanced the mechanical strength and chemical stability.In summary,the MMMs with high retention rate,strong permeability,and anti-fouling ability were successfully prepared.

一类强2-正系统的整数值Lyapunov函数

针对双向循环负反馈系统对应的线性系统,即强2-正系统构造了整数值Lyapunov函数σ(·)。该函数定义在?n中的一个开稠集上,它表示n维向量坐标之间符号改变的次数。通过定义两类与σ(·)相关的整数值函数σ_(m)(·)、σ_(M)(·),借助这些函数具有的特性,证明了σ(·)沿着解的轨道具有衰减性;同时,如此定义的整数值Lyapunov函数若满足轨道衰减性,那么所对应线性系统几乎处处是一个强2-正系统。该函数为进一步研究负反馈系统的结构稳定性以及极限集的嵌入性质等提供了有效的研究工具,对于深入了解该系统的动力学提供了重要参考。

镜铁山式铁矿选矿过程中K_(2)O含量走向分析

针对镜铁山式难选氧化铁矿矿石特点及酒钢选矿厂现有工艺流程,为减少酒钢高炉吨铁碱金属负荷,尤其是K_(2)O含量,确保后续烧结及炼铁工序顺利进行,对选矿不同工艺流程中的原矿矿石性质进行研究,发现K_(2)O主要赋存矿物为白云母,镜铁山矿经筛分分为强磁粉矿和块矿,块矿经过焙烧抛废后其K_(2)O含量基本稳定在0.405%,满足炼铁精矿质量要求;强磁粉矿中K_(2)O含量较高,通过考察现场强磁选流程,发现立环机及筒式磁选机对脉石矿物白云母具有一定的分选作用,在对设备运行参数进行调整后可进一步将K_(2)O富集在尾矿中,最终可获得铁精矿品位44.90%,回收率59.71%,K_(2)O品位为0.362%的合格铁精矿,为适时控制难选氧化铁矿石选别产品综合铁精矿质量提供一定的数据参考。

塔河油田强底水砂岩油藏CO_(2)/N_(2)驱提高采收率机理

塔河油田强底水砂岩油藏开发后期,受强非均质性和底水锥进影响,大部分水平井出现了点状水淹,导致低产低效井增多,油藏含水率不断上升,井间剩余油动用难,且该油藏具有高温、高盐特点,常规提高采收率技术难以取得较好的开发效果。因此,主要通过高温高压三维物理模型进行油藏的模拟,采用注CO_(2)/N_(2)(体积比为7∶3)混合气提高强底水砂岩油藏采收率。一方面,CO_(2)与原油易混相,能够大幅度地提高驱油效率;另一方面,N_(2)具有较好的压锥效果,在一定程度上抑制了强底水快速锥进,提高油藏的波及系数。这样使“驱油”与“压锥”进行有机结合,大大提高了油藏采收率。同时,对比不同注气方式、不同注气速度和不同注采部位等驱油条件,优选注气参数。实验结果表明:注入CO_(2)/N_(2)后地层原油体积膨胀了21%,黏度降低了24.9%;CO_(2)/N_(2)混合气与原油的最小混相压力为39.62 MPa;优选出了最佳的注入参数:注气速度为1 mL/min(提高采收率幅度为14.25%)、注气方式为水气交替注入(提高采收率幅度为15.8%)、注采部位为高注低采(提高采收率幅度为14.5%)。研究结果为塔河油田强底水砂岩油藏CO_(2)/N_(2)混合气驱先导试验提供可靠实验依据。

Strong ground motion simulation for the 2013 Lushan M_W6.6 earthquake, Sichuan, China, based on the inverted and synthetic slip models

It is well known that quantitative estimation of slip distributions on fault plane is one of the most important issues for earthquake source inversion related to the fault rupture process. The characteristics of slip distribution on the main fault play a fundamental role to control strong ground motion pattern. A large amount of works have also suggested that variable slip models inverted from longer period ground motion recordings are relevant for the prediction of higher frequency ground motions. Zhang et al. （Chin J Geophys 56：1412-1417, 2013） and Wang et al. （Chin J Geophys 56：1408-1411,2013） published their source inversions for the fault rupturing process soon after the April 20, 2013 Lushan earthquake in Sichuan, China. In this study, first, we synthesize two forward source slip models： the value of maximum slip, fault dimension, size, and dimension of major asperities, and comer wave number obtained from Wang＇s model is adopted to constrain the gen- eration of k-2 model and crack model. Next, both inverted and synthetic slip models are employed to simulate the ground motions for the Lushan earthquake based on the stochastic finite-fault method. In addition, for a comparison purpose, a stochastic slip model and another k-2 model （k 2 model II） with 2 times value of comer wave number of the original k-2 model （k 2 model I） are also employed for simulation for Lushan event. The simulated results characterized by Modified Mer- calli Intensity （MMI） show that the source slip models based on the inverted and synthetic slip distributions could capture many basic features associated with the ground motion patterns. Moreover, the simulated MMI distributions reflect the rupture directivity effect and the influence of the shallow velocity structure well. On the other hand, the simulated MMI bystochastic slip model and k 2 model II is apparently higher than observed intensity. By contrast, our simulation results show that the higher frequency ground motion is sensitive to the degree of slip roughness; therefore, we suggest that, for realistic ground- motion simulations due to future earthquake, it is imperative to properly estimate the slip roughness distribution.

CaTiF_(6)·2H_(2)O:Mn^(4+)窄带红色荧光粉的发光性能及其高显指暖白光LED应用

报道了一种新型的Mn^(4+)掺杂水合六氟钛酸钙CaTiF_(6)·2H_(2)O:Mn^(4+)红色荧光粉,详细研究了基质的结构转变和荧光粉的发光性能及高显色指数(显指)暖白光LED应用。CaTiF_(6)·2H_(2)O:Mn^(4+)在130~200℃间脱水转化为CaTiF_(6):Mn^(4+),荧光光谱发生改变,重新吸附水分子可恢复到CaTiF_(6)·2H_(2)O:Mn^(4+),发光性能不可逆。重要的是,该荧光粉在较长波626 nm和635 nm处分别发射锐线极强的零声子线(ZPL)和ν6振动峰,色坐标为(0.701,0.299),更接近人眼敏感的红光边界650 nm(色坐标x~0.72,y~0.28),有助于提高暖白光LED的显色指数、拓宽背光源的色域。晶体结构和晶体场强度计算指出,Mn^(4+)在CaTiF_(6)·2H_(2)O:Mn^(4+)中占据低对称性的格位,所受到的晶体场强度较弱,Mn—F键的共价性较强。另外,通过表面疏水化显著提升了荧光粉耐湿性能,共掺小离子半径的Si^(4+)增强了荧光粉发光热稳定性。以CaTiF_(6)·2H_(2)O:Mn^(4+)作为红光成分,获得了高显色指数(R_(a)=90,R_(9)=68)的暖白光LED,在高品质的暖白光照明中具有潜在的应用。

SWOT Analysis on Agricultural Enterprises Implementing B2C E-commerce——A Case Study of Wuding Strong Chicken Farming Enterprises

This paper first introduced current situations of agricultural enterprises using B2C e-commerce to sell agricultural products.Then,using SWOT method,it analyzed strengths,weaknesses,opportunities,and threats of Wuding strong chicken farming enterprises implementing B2C e-commerce.Finally,it came up with recommendations for Wuding strong chicken farming enterprises implementing B2C e-commerce.

SOME PROPERTIES OF STRONGLY MONOTONICALLY T2 SPACES

This paper investigates Buck＇s question about which class of spaces is strongly monotonically T2,and if other properties are combined with strongly monotonically T2,which class of spaces could be got. Based on having a cushioned pair-base space and compact strongly monotonically T2 space,some results （Theorems 1--3） are obtained.

Strong Law of Large Numbers for a 2-Dimensional Array of Pairwise Negatively Dependent Random Variables

In this paper, we obtain the strong law of large numbers for a 2-dimensional array of pairwise negatively dependent random variables which are not required to be identically distributed. We found the sufficient conditions of strong law of large numbers for the difference of random variables which independent and identically distributed conditions are regarded. In this study, we consider the limit as which is stronger than the limit as m× n→?∞ when m, n →?∞?are natural numbers.